CG Oncology Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

CGON$75.99+17.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets

(In thousands, except share and per share amounts)

	March 31,	December 31,
	2024	2023
Assets · (unaudited)
Current assets:
Cash and cash equivalents	$77,468	$8,266
Marketable securities	489,040	179,408
Prepaid expenses and other current assets	11,949	6,358
Accounts receivable - other	153	92
Total current assets	578,610	194,124
Property and equipment, net	77	69
Operating lease right-of-use assets	368	422
Other assets	53	19
Deferred offering costs	—	4,667
Total assets	$579,108	$199,301
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$4,658	$3,242
Success fee liability, current portion	—	352
Operating lease liabilities, current portion	220	217
Accrued expenses and other current liabilities	5,106	10,443
Total current liabilities	9,984	14,254
Success fee liability, non-current	—	13
Operating lease liabilities, net of current portion	184	244
Total liabilities	10,168	14,511
Commitments and contingencies (Note 5)
Redeemable convertible preferred stock:
Series A-1 redeemable convertible preferred stock, $0.0001 par value per share; zero and 5,075,000 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $3,570 as of March 31, 2024 and December 31, 2023, respectively	—	3,570
Series B redeemable convertible preferred stock, $0.0001 par value per share; zero and 11,973,000 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023; liquidation value of $0 and $10,000 as of March 31, 2024 and December 31, 2023, respectively	—	10,000
Series C redeemable convertible preferred stock, $0.0001 par value per share; zero and 73,598,283 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $22,000 as of March 31, 2024 and December 31, 2023, respectively	—	22,000
Series D redeemable convertible preferred stock, $0.0001 par value per share; zero and 53,271,754 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $47,300 as of March 31, 2024 and December 31, 2023, respectively	—	47,300
Series E redeemable convertible preferred stock, $0.0001 par value per share; zero and 112,422,700 shares authorized, issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $120,000 as of March 31, 2024 and December 31, 2023, respectively	—	120,000
Series F redeemable convertible preferred stock, $0.0001 par value per share; zero and 81,587,937 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $105,020 as of March 31, 2024 and December 31, 2023, respectively	—	105,020
Stockholders’ equity (deficit):
Common stock, $0.0001 par value per share; 700,000,000 and 493,530,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 66,636,252 and 5,222,283 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	7	—
Additional paid-in capital	715,807	6,842
Accumulated deficit	(146,874)	(129,942)
Total stockholders' equity (deficit)	568,940	(123,100)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$579,108	$199,301

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.